Diseases of the prostate gland are common in dogs, accounting for up to 10% of the pathological conditions in sexually intact male dogs examined by veterinary surgeons.1 Among these, malignant neoplasias are rare, with estimated prevalences of prostate gland carcinoma of 0.2% and 0.6%.2 Because cancer of the prostate gland is highly aggressive, with macroscopic metastasis detected at necropsy in 80% of affected animals,3 an early diagnosis is crucial for the management of patients. In contrast to the United States, where most of the dogs are neutered, the percentage of sexually intact animals in Europe can be highly variable among countries. In some countries, most of the animals are gonadally intact4 and thus more prone to pathological conditions of the prostate gland. Moreover, dogs are the only animals other than humans that naturally develop prostate gland cancer; therefore, dogs can serve an important role for the study of prostate gland disease of humans.5 Thus, investigation of the prostate gland has been a focus of recent scientific studies.
A noninvasive method to diagnose prostate gland diseases in dogs relies on clinical examination, laboratory analysis, and diagnostic imaging. Radiographic and ultrasonographic findings are not pathognomonic for any prostate gland diseases.1 Contrast-enhanced ultrasonography has been described as an additional aid for use in differentiating benign from malignant prostate gland lesions,6 but this technique is not routinely used in veterinary medicine.
The incidence of prostate gland cancer is much higher in human medicine than in veterinary medicine, and the incidence of cancer progressively increases with age.7 Means of diagnosis with high specificity and sensitivity and that also can serve as adequate screening methods have been evaluated. Use of MRI to provide a combination of morphological and functional images has become the standard method for investigation of pathological conditions of the prostate gland.7 Morphological imaging (typically T2-weighted images and T1-weighted precontrast and postcontrast images) is commonly used for detection and localization of possible lesions, identification of changes after biopsy, and monitoring of disease. In addition, functional MRI (PW-MRI, DW-MRI, and spectroscopic imaging) have been recommended as potential complements.8 Perfusion-weighted MRI (or dynamic contrast-enhanced MRI) is widely used as a tool to discriminate between benign and malignant lesions9 and for accurate localization of tumors (primarily in the peripheral zone of the prostate gland), local staging of tumors, and detection of tumor recurrence.10
In human medicine, DW-MRI with corresponding quantification of the ADC value has been used to discriminate malignant neoplasia from normal prostate gland tissue or benign processes.11,12 Values for ADC correlate with the score of aggressiveness of prostate gland tumors.13,14
The availability of cross-sectional imaging modalities is increasing in veterinary medicine, and the use of such modalities to assess the prostate gland is garnering interest. There is a paucity of reports and lack of detailed description of the prostate gland and pathological conditions of the prostate gland. To the authors' knowledge, results of functional MRI of the prostate gland of clinically normal dogs have not been reported. Therefore, the objective of the study reported here was to assess the feasibility for use of PW-MRI and DW-MRI in the evaluation of the prostate gland of dogs in a clinical setting and to describe the perfusion pattern as well as the DW-MRI characteristics of the prostate gland in a sample of healthy sexually intact adult dogs. These data would provide baseline information for use in evaluation of pathological conditions of the prostate gland of dogs.
Supported by the Marie-Louise von Muralt Foundation. The authors declare that there were no conflicts of interest.
Apparent diffusion coefficient
Region of interest
Aloka Alpha 10 ultrasound machine, Hitachi Medical Systems Europe Holding AG, Zug, Switzerland.
7.5 MHz (5 to 10 MHz), Aloka UST-9120, Hitachi Aloka Medical America, Wallingford, Conn.
12 MHz (5 to 13 MHz), Aloka UST-5412, Hitachi Aloka Medical America, Wallingford, Conn.
Philips Ingenia scanner, Philips AG, Zurich, Switzerland.
dStream Flex M, phased-array detection, 6 channels, Philips AG, Zurich, Switzerland.
Omniscan, GE Healthcare AG, Glattbrugg, Switzerland.
Philips Intellispace Ingenia, Philips Medical System, Best, Netherlands.
SPSS Statistics, version 220.127.116.11, IBM Corp, Chicago, Ill.
1. Lévy X, Nizanski W, von Heimendahl A, et al. Diagnosis of common prostatic conditions in dogs: an update. Reprod Domest Anim 2014;49(suppl 2):50–57.
3. Cornell KK, Bostwick DG, Cooley DM, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 2000;45:173–183.
4. Torres de la Riva G, Hart BL, Farver TB, et al. Neutering dogs: effects on joint disorders and cancers in Golden Retrievers. PLoS One 2013;8:e55937.
6. Vignoli M, Russo M, Catone G, et al. Assessment of vascular perfusion kinetics using contrast-enhanced ultrasound for the diagnosis of prostatic disease in dogs. Reprod Domest Anim 2011;46:209–213.
7. Bonekamp D, Jacobs MA, El-Khouli R, et al. Advancements in MR imaging of the prostate: from diagnosis to interventions. Radiographics 2011;31:677–703.
8. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99–109.
9. Padhani AR, Harvey CJ, Cosgrove DO. Angiogenesis imaging in the management of prostate cancer. Nat Clin Pract Urol 2005;2:596–607.
10. Somford DM, Futterer JJ, Hambrock T, et al. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008;16:685–695, ix.
11. Esen M, Onur MR, Akpolat N, et al. Utility of ADC measurement on diffusion-weighted MRI in differentiation of prostate cancer, normal prostate and prostatitis. Quant Imaging Med Surg 2013;3:210–216.
12. Issa B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002;16:196–200.
13. Hambrock T, Somford DM, Huisman HJ, et al. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011;259:453–461.
14. Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012;2012:374805.
15. Mattoon JS, Nyland TG. Prostate and testes. In: Nyland TG, Mattoon JS, eds. Small animal diagnostic ultrasound. Philadelphia: WB Saunders, 2002;250–266.
16. Günzel-Apel AR, Mohrke C, Poulsen Nautrup C. Colour-coded and pulsed Doppler sonography of the canine testis, epididymis and prostate gland: physiological and pathological findings. Reprod Domest Anim 2001;36:236–240.
17. Powe JR, Canfield PJ, Martin PA. Evaluation of the cytologic diagnosis of canine prostatic disorders. Vet Clin Pathol 2004;33:150–154.
18. Paclikova K, Kohout P, Vlasin M. Diagnostic possibilities in the management of canine prostatic disorders. Vet Med (Praha) 2006;51:1–13.
19. Yung AC, Oner AY, Serfaty JM, et al. Phased-array MRI of canine prostate using endorectal and endourethral coils. Magn Reson Med 2003;49:710–715.
20. Susil RC, Krieger A, Derbyshire JA, et al. System for MR image-guided prostate interventions: canine study. Radiology 2003;228:886–894.
21. Sun F, Baez-Diaz C, Sanchez-Margallo FM. Canine prostate models in preclinical studies of minimally invasive interventions: part I, canine prostate anatomy and prostate cancer models. Transl Androl Urol 2017;6:538–546.
22. Chen Y, Xu S, Squires A, et al. MRI guided robotically assisted focal laser ablation of the prostate using canine cadavers. IEEE Trans Biomed Eng 2018;65:1434–1442.
23. Cheng HL, Haider MA, Dill-Macky MJ, et al. MRI and contrast-enhanced ultrasound monitoring of prostate microwave focal thermal therapy: an in vivo canine study. J Magn Reson Imaging 2008;28:136–143.
25. Lai CL, van den Ham R, van Leenders G, et al. Comparative characterization of the canine normal prostate in intact and castrated animals. Prostate 2008;68:498–507.
26. Barrett T, Priest AN, Lawrence EM, et al. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR Am J Roentgenol 2015;205:W585–W593.
27. Kim CK, Park BK, Kim B. Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol 2010;194:1461–1469.
28. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007;63:335–350.
29. Hara N, Okuizumi M, Koike H, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140–147.
30. Fütterer JJ, Heijmink SWTPJ, Scheenen TWJ, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449–458.
31. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425–430.
32. Jones DJ, Stehling LC, Zauder HL. Cardiovascular responses to diazepam and midazolam maleate in the dog. Anesthesiology 1979;51:430–434.
33. Lowseth LA, Gerlach RF, Gillett NA, et al. Age-related changes in the prostate and testes of the Beagle dog. Vet Pathol 1990;27:347–353.
34. Ren J, Huan Y, Wang H, et al. Diffusion-weighted imaging in normal prostate and differential diagnosis of prostate diseases. Abdom Imaging 2008;33:724–728.